Lisa H. Butterfield, Ph.D. is an Adjunct Professor of Microbiology and Immunology, University California San Francisco and a consultant in immuno-oncology.
Her research is focused on cancer vaccines, immune profiling and cellular therapies for melanoma, hepatocellular cancer and other tumor types. Dr. Butterfield was most recently Vice President, Research and Development at the Parker Institute for Cancer Immunotherapy, where she supported cell therapy initiatives and clinical trial biospecimen and biomarker projects.
Previously, she was a tenured Professor of Medicine, Surgery, Immunology and Clinical and Translational Science at the University of Pittsburgh (2003-2018) and Director of the Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory.
She has a PhD in Biology from UCLA, followed by postdoctoral fellowships in Cellular Immunology and Cancer Gene Therapy also at UCLA.
She was the President of the Society of Immunotherapy of Cancer (SITC, 2017-2018) and a member of the SITC Executive Committee (2015-2020). She led the Immunology Reference Lab for the ECOG-ACRIN NCI cooperative group (2006-2018) and collaborates on biomarker studies in many clinical trials. She has published over 185 peer-reviewed manuscripts, reviews and book chapters, and mentored over 20 students and postdocs. She co-leads the SITC Women’s Leadership Institute and is a co-Editor of the SITC textbook “Cancer Immunotherapy: Principles and Practice” 1st and 2nd editions.
John Haanen finished his MD at Leiden University cum laude in 1988. From 1988 till 1991 he performed his PhD studies at the Division of Immunohematology & Blood Bank of Leiden University Medical Center and at DNAX, Research Institute, Palo Alto, California, US and defended his PhD thesis on human CD4+ helper T1 cells reactive against mycobacteria in November 1991. He trained in internal medicine in hospitals in Leiden (university hospital) and The Hague (regional hospital).
In 1996 he was registered as internist. As staff member of the department of Internal Medicine at Leiden University Medical Center (LUMC) (Head: Prof Edo Meinders), he worked as internist at the internal medicine intensive care unit for the duration of one year (supervision by Prof Hans van der Hoeven).
From October 1997 - October 1999 he did a full-time post-doctoral fellowship at the Division of Immunology of the Netherlands Cancer Institute (NKI), Amsterdam, (Head: Prof Ada Kruisbeek) on preclinical tumour immunology and started his long-term collaboration with Prof Ton Schumacher.
From October 1999 – October 2001 he trained in medical oncology (Head: Prof Sjoerd Rodenhuis) and received a permanent position as (consultant) medical oncologist (division of medical oncology) and research group leader (division of immunology) at NKI.
His research has been focused on the development of innovative immunotherapies in close collaboration with Prof. Ton Schumacher. The Haanen lab developed a novel therapeutic DNA vaccination strategy from Bench to Bedside; The Haanen/Schumacher lab developed TCR gene therapy, again from Bench to Bedside. In 2008, he received an endowed professorship on Translational Immunotherapy of Cancer at LUMC.
From 2009 till 2018 he headed the Division of Medical Oncology at NKI. During this period, the division doubled in size, and clinical immunotherapy was introduced. In July 2018 he accepted a position as CSO Immunotherapy, one of the major research themes at NKI, to increase immunotherapy research, facilitate more translational research programs and start building the NKI Center for Cellular Therapy (solid cancers). His current research spreads over development of cellular therapies for solid tumours, neoadjuvant immunotherapies (renal cell cancer, involvement in GI cancers and head and neck cancers), and biomarker research. His clinical specialty is in melanoma and other skin cancers, kidney cancer and management of immune-related adverse events.
He has co-authored over 500 peer-reviewed articles, serves on the Editorial Board of ESMO Open, Cancer Treatment Reviews and Kidney Cancer. He is currently Editor-in-Chief of ESMO IOTECH. John Haanen was Scientific Co-Chair of ESMO Immuno-Oncology Congress from 2016-2019, and Scientific Chair of the ESMO 2020 Congress. He is or has been an active member of several ESMO Committees and Task Forces: Women for Oncology (W4O), Resilience Task Force, Gender Medicine Task Force, Integrated Immunotherapy Faculty Member and since 2019 serves as a member of the ESMO Council. Since 2017, he is a member of the Central Committee for Research involving Human Subjects (CCMO).
Sandra D'angelo is an Oncologist at Memorial Sloan Kettering Cancer Center in New York. Dangelo has been practicing medicine for over 18 years and is highly rated in 34 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Merkel Cell Carcinoma, Synovial Sarcoma, Liposarcoma, and Liver Embolization. She is licensed to treat patients in New York. Dangelo is currently accepting new patients.
Her clinical research consists of co-authoring 95 peer-reviewed articles and participating in 19 clinical trials in the past 15 years
Associate Professor Ravindran Kanesvaran is a Deputy Chair and Senior Consultant in the Division of Medical Oncology of the National Cancer Centre Singapore ( NCCS). He is also an Associate Professor at Duke-NUS Graduate Medical School and a clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He did his medical oncology training at NCCS and a post-exit fellowship in GU cancers and geriatric oncology at the Duke Cancer Institute, North Carolina, USA.
He is actively involved in graduate medical education and was the Program Director of the Medical Oncology Senior Residency Program from 2018-2021. At Duke NUS medical school, he was director of the Fundamentals in Clinic Practice course from 2017-2021. He was also the founding medical director of the medical oncology satellite centre at Sengkang Hospital ( 2018-2021). He has been awarded numerous awards for his outstanding clinical work including the following; Singhealth Outstanding Clinician of the year 2021, Singhealth Excellent Service Award 2018 (Silver), 2019 ( Gold ), and 2021 ( STAR).
His research interests include genito-urinary oncology and geriatric oncology. He has published in a number of well-known peer-reviewed journals including the Journal of Clinical Oncology and Lancet Oncology. He is the author of over 150 peer-reviewed papers and of several textbook chapters. He has also been awarded a number of awards including the American Society of Clinical Oncology (ASCO GU) Merit Award 2009, the American Association for Cancer Research (AACR) scholar-in-training Award 2010, and the European Society of Medical Oncology (ESMO) fellowship award 2012. He is currently the Immediate Past President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He is on the Editorial board of a number of leading journals including ESMO Open, Journal of Geriatric Oncology, Therapeutic Advances in Medical Oncology (TAM), and Annals of the Academy of Medicine Singapore.
He had been appointed as the European Society of Medical Oncology (ESMO) Faculty in 2015-2016 in Geriatric Oncology and 2016-2020 in GU Oncology ( 2017- to date). He is currently part of the SIOG-ESMO Cancer in the Elderly workgroup. He is an ESMO Council Member and member of the ESMO Public Policy Steering Committee as Chair of the ESMO Asia Pacific Public Policy Committee since 2018. He has been actively involved in the ESMO Leaders Generation Programme ( LGP) as faculty in 2018 and later as Co-Chair of the ESMO Asia LGP since 2019 and is a member of the ESMO Leadership Generation Task Force since 2019. He was the host and steering committee member of the first ESMO Asia meeting in 2015. Recently he led the development of the ESMO Pan Asian Adapted Guidelines (PAGA) for both renal cell carcinoma ( 2021) and Prostate Cancer ( 2021).
He is currently President ( 2020-2022) and the National Representative for Singapore in the International Society of Geriatric Oncology (SIOG). Prior to this, he was Treasurer ( 2016-2018) and a Board member of SIOG. He was awarded the first National Representative of the Year in 2014 by SIOG at the Annual Meeting in Lisbon that year.
He is also the Vice Chairman of the Singapore Cancer Society (SCS), which is one of the largest non-governmental cancer-based charities in the region. Apart from his role on the council of SCS, he is also the chair of the Cancer Treatment Fund ( which provides funding for cancer drugs for patients), the Medical and Professional Audit Committee, and the Cancer rehabilitation committee.
Solange Peters, MD-PhD, achieved her MD from the Medical School at the University of Lausanne in 1998, following this she attended the Microbiology Institute at the University of Lausanne until 2002, concluding with a MD-PhD thesis on new HIV drug-resistance mechanisms.
From 2002-2006, Prof. Peters did her residency in Internal Medicine, followed by a Fellowship at the Multidisciplinary Oncology Centre at the University Hospital of Lausanne. In September 2006, she sat the ESMO Examination in Oncology and was awarded the ESMO Best European Exam result. This was shortly followed by the SSMO (Swiss Society of Medical Oncology) oral exam November 2006. In 2013, Prof. Peters received the title of Lausanne University Private Docent (PD-MER) and was appointed Professor and Head of Medical Oncology at the Faculty of Biology and Medicine in Lausanne successively in 2015 and 2016.
Prof. Peters is currently in charge of teaching and patient care in the area of medical oncology and thoracic malignancies at the Department of Oncology of Lausanne University, where she is building a translational programme in collaboration with the molecular oncology laboratories of the Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute.
Prof. Peters’ main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally-advanced NSCLC as well as clinical and translational cancer immunotherapy. Her current research projects as a chair are focused on multimodality curative-intent treatment of stage III NSCLC, combined immunotherapy for the treatment of NSCLC, SCLC, thymic malignancies and mesothelioma, as well as targeted therapies in oncogene-addicted NSCLC. She acts as the local PI of lung trials opened in Lausanne Cancer Centre, focused on phase I, predictive biomarkers and NSCLC immunotherapy. In addition, she is a co-PI of several other trials.
She is active in academic trials building and organisation, as well as related databases for the ETOP (European Thoracic Oncology Platform), where she is responsible for communication, scientific coordination and member of the Foundation Council.
Prof. Solange Peters is an active member of the educational programme within ESMO. Prof. Peters is currently President (2020 – 2022) of the European Society for Medical Oncology (ESMO) and a member of the ESMO Faculty for Lung and Other Thoracic Cancers. She was previously Chair of the ESMO Women for Oncology Committee, member of the ESMO E-Learning and CME Committee, elected ESMO Swiss National Representative, and was also Subject Editor for the ESMO Guidelines Working Group. She was the scientific chair of ELCC 2016 and Scientific Chair of the ESMO 2018 annual congress in Munich.
She is in parallel active in IASLC and served as a Board Member. She is a member of AACR (American Association for Cancer Research) and EORTC (European Organisation for Research and Treatment of Cancer).
Of national organisations, Prof. Peters is Vice President of SAMO (Swiss Academy for Multidisciplinary Oncology), member of SAKK (Swiss Group for Clinical Cancer Research) – where she was Co-Chair of the Swiss Lung Cancer Research Group from 2010-2019, FMH (Association of Swiss Physicians) and ASMAC/VSAO (Association of Swiss Interns and Residents) and was the president of FOROME (Association Romande pour la formation continue en oncologie médicale) for 5 years.
Prof. Peters has authored more than 250 peer-reviewed manuscripts and book chapters, served as an Associate Editor of ‘Lung Cancer’ and was the Deputy Editor of the ‘Journal of Thoracic Oncology’ (JTO), the official journal of IASLC, until 2020. She was Editor in Chief of Cancer Treatment Communications. In addition, she acts as Associate Editor for Annals of Oncology, Associate Editor for ‘Frontiers in Pharmacology of Anti-Cancer Drugs’ and Review Editor for ‘Frontiers in Thoracic Oncology’. She is the author of numerous articles in peer-reviewed publications as well as book chapters and abstracts and the Co-Editor of the book ‘Perspectives in Thoracic Oncology’ (UNI-MED), the book series ‘Progress in Tumor Research’ (Karger) as well as new therapeutic strategies in lung cancers (Springer).
RCSI Professor of Medical Oncology; Consultant Medical Oncologist at Beaumont RCSI Cancer Centre, Dublin
Professor, Tenured Senior Member
Director, Cutaneous Clinical & Translational Research
Moffitt Cancer Center & Research Institute
Marcin Dzienis is a medical oncologist working at the Gold Coast University and Private Hospitals. He completed his undergraduate medical degree in Poland before migrating to London and then to Queensland where he underwent training as a physician and a medical oncologist. Subsequently, he undertook a combined head-and-neck and skin cancer fellowship at the Princess Alexandra Hospital and the Translational Research Institute in Brisbane. Currently, he continues to provide patient care with clinical trial involvement and ties to Griffith University.
Ranjana H. Advani, MD is the Saul Rosenberg Professor of Lymphoma and serves as the Physician Leader of the Lymphoma Clinical Care Program. She specializes in research and treatment of Hodgkin and non-Hodgkin lymphomas and has developed a broad collaborative investigative program, encompassing clinical trials and translational correlates. She is the Principle Investigator on numerous clinical trials. She currently serves on the National Comprehensive Cancer Network (NCCN) non Hodgkin and Hodgkin Lymphoma (vice chair) guidelines panel, Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG) and the National Cancer Institute Lymphoma Steering Committee.
Professor Jean-Yves Blay, MD, PhD is a medical oncologist, Professor of Medicine at the University Claude Bernard in Lyon, General Director of the Centre Leon Berard, the Comprehensive Cancer Centre of Lyon France since December 2014, researcher and Professor at the University Claude Berard, France. Since 2019, he serves as the President of the French Federation of Cancer Centers Unicancer, the network of 18 Comprehensive Cancer Centers in France.
His work focuses on sarcoma, genomics and targeted treatment of cancer, immune-oncology, and the relationship between tumour immunologic microenvironment and malignant cells, with the goal of clinical applications in the field of diagnosis, prognosis and treatment. As director of the French Network of reference centers for Sarcoma since 2010 and as the coordinator of European Reference Network on rare adult cancers, EURACAN, his work also focuses on the improvement of organisation of routine treatments and clinical trials at the national and EU level to improve the survival, quality of care and quality of life of cancer patients.
Professor Blay has co-authored 880 peer-reviewed articles and book chapters on Pubmed, 1630 quoted on web of science, and distinguished as Highly Cited Researcher by Clarivate since 2019. He advises various national and international institutions and research organisations, and is an active member of several oncology scientific organisations and societies, such as ESMO, CTOS, ASCO and AACR.
He has been distinguished with the Hamilton-Fairley Award from ESMO (2012) and the Henry and
Mary-Jane Mitjaville prize from the National Academy of Medicine (2013), the Duquesne Prize of the League contre le Cancer, was awarded the Nina Axelrad Lecture and Prize by the Connective Tissue Oncology Society, Rome (Nov 2018) and received the San Salvatore Prize, San Salvatore Foundation, Switzerland (Nov 2020).
Within ESMO, he served in several positions, including as Scientific Chair for the Sarcoma track and contributes since 2005 to the Clinical Practice Guidelines on this theme. He was the Scientific Co-Chair of the ESMO 2019 Congress in Barcelona (29,900 participants).
Professor Blay is managing several research cooperative groups and networks. He is the Director of the LYRICAN Innovative programme of excellence for cancer research granted by the INCA since 2012. He is also President of the French Sarcoma Group since 2005, the Network director of NETSARC+ network of sarcoma reference center for the INCA since 2019. He serves as Secretary for the World Sarcoma Network (WSN), a think tank of all worldwide sarcoma research groups. He serves as the Network Coordinator of ERN-EURACAN, designated by the EU Commission in 2016 to improve the quality of care for patients with rare cancers in the European Union. Previously, he served as the President of EORTC between 2009 and 2012. He was the former Principal Investigator of Conticanet, an EU Commission network of excellence of FP6, and the PI of the FP7 project EUROSARC.
Dr. Pooja Advani is a Consultant and Assistant Professor of Medicine at Mayo Clinic. She earned her medical degree in Mumbai, India and completed her residency at the State University of New York. She is a graduate of the Mayo Clinic Hematology and Oncology Fellowship program where she also served as the Chief Fellow.
She is a breast medical oncologist and the Director of the Robert and Monica Jacoby Center for Breast Health at Mayo Clinic, Jacksonville. She is a laboratory-based physician-scientist. Her current research interests are centered on understanding and leveraging the molecular underpinnings of cancer biology to help develop novel therapeutics to improve patient outcomes.
Dr. Advani has authored several peer reviewed publications in prestigious journals, editorials, and book chapters. She has been a recipient of a number of grant funding in support of her research interests including US Department of Defense and National institute of Health funding. She also serves as the principal investigator of several Phase II/III breast cancer clinical trials including investigator-initiated interventional trials.
Dr. Advani serves as a core faculty member for the Mayo Clinic Florida Hematology-Oncology fellowship program and career advisor for medical students. She has also earned several awards for excellence in patient care.
Prof, Medicine, Harvard Medical School. Director, Multiple myeloma program, Medical Oncology, Massachusetts General Hospital, Boston, USA
Vivek Roy, M.D., is a hematologist-oncologist with more than 25 years of both clinical and research experience specializing in hematologic malignancies and stem cell transplantation. His predominant professional activity is as a clinician providing care to patients with blood disorders and patients undergoing stem cell transplantation.
As a researcher, Dr. Roy has studied hematopoietic stem cells in the laboratory, characterizing stem cells obtained from disparate sources. His research activities are focused on novel approaches to improve the outcomes of hematopoietic stem cell transplantation, stem cell mobilization and clinical trials to develop novel therapies for multiple myeloma, amyloidosis, and hematologic malignancies.
Dr. Gnjatic received his Ph.D. in immunology from the University of Paris VII after completing a fellowship at the Institut Cochin in Paris. Following a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, he joined the Ludwig Institute for Cancer Research at MSKCC, where he eventually became an associate member and was named director of Immunological Monitoring at the Ludwig Center for Cancer Immunotherapy. In 2013, Dr. Gnjatic was appointed to his current position of associate professor of medicine at the Tisch Cancer Institute and the Precision Immunology Institute, part of the Icahn School of Medicine at Mount Sinai in New York. He also serves as associate director of the Human Immune Monitoring Core at Mount Sinai. Dr. Gnjatic’s research focuses on human antigen-specific immune responses to tumor antigens, in an attempt to define new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail. He also studies the mechanisms of antigen presentation to T cells, the impact of immunoregulation on tumor antigen-specific responses, and characterization of the tumor-immune microenvironment. By supporting correlative studies and biomarker discovery from peripheral blood and at the tissue site, Dr. Gnjatic’s work has established the immunological basis for testing human cancer immunotherapies in over 40 clinical trials, and has resulted in more than 150 publications in high-impact, peer-reviewed journals as well as numerous patents.
Professor James Larkin is a Medical Oncologist specialising in the treatment of melanoma and cancers of the kidney.
Professor Larkin grew up in North Cornwall before taking a first in Natural Sciences from Cambridge University. He undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008.
His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies.
He is a past National Institute for Health Research (NIHR) National Specialty Lead for Early Phase Oncology Trials, as well as a past Chair of the NCRI Renal Cancer Clinical Studies Group, The Royal Marsden/ICR Committee for Clinical Research and the CRUK Clinical Research Monitoring Panel.
Professor Larkin is currently Vice Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at The Royal Marsden/ICR Biomedical Research Centre.
In 2018 he was elected as a Fellow of the Academy of Medical Sciences. Since 2019 he has been Vice Chair of the Medical Oncology Specialist Advisory Committee for the Joint Royal Colleges of Physicians Training Board and in 2020 he was appointed as an NIHR Senior Investigator.
He serves as a medical advisor to the patient advocacy group Melanoma UK, as a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.
MD MSc is a career-long clinical and translational researcher as well as education-focused, academic clinician with sub-specialist interest in all aspects of triple negative breast cancer (TNBC) and young women with breast cancer.
Prof Dent achieved her MD from McMaster University in Hamilton, Ontario, Canada and then completed her internal medicine and medical oncology residency at the Princess Margaret Hospital and the Sunnybrook Odette Cancer Center in Toronto, Canada.
Prof Dent moved to Singapore where she is now Senior Consultant at the National Cancer Center in Singapore (NCCS).